Standard

Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica : A scoping review by the OMERACT irAE working group. / Ghosh, Nilasha; Couette, Nina; van Binsbergen, Wouter H. et al.

In: Seminars in arthritis and rheumatism, Vol. 58, 152110, 01.02.2023.

Research output: Contribution to journalReview articleAcademicpeer-review

Harvard

Ghosh, N, Couette, N, van Binsbergen, WH, Weinmann, SC, Jivanelli, B, Shea, B, Bass, AR, Benesova, K, Bingham, CO, Calabrese, C, Cappelli, LC, Chan, KK, Choy, E, Daoussis, D, Goodman, S, Hudson, M, Jamal, S, Leipe, J, Lopez-Olivo, MA, Suarez-Almazor, M, van der Laken, CJ, Meara, AS, Liew, D & Kostine, M 2023, 'Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: A scoping review by the OMERACT irAE working group', Seminars in arthritis and rheumatism, vol. 58, 152110. https://doi.org/10.1016/j.semarthrit.2022.152110

APA

Ghosh, N., Couette, N., van Binsbergen, W. H., Weinmann, S. C., Jivanelli, B., Shea, B., Bass, A. R., Benesova, K., Bingham, C. O., Calabrese, C., Cappelli, L. C., Chan, K. K., Choy, E., Daoussis, D., Goodman, S., Hudson, M., Jamal, S., Leipe, J., Lopez-Olivo, M. A., ... Kostine, M. (2023). Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: A scoping review by the OMERACT irAE working group. Seminars in arthritis and rheumatism, 58, [152110]. https://doi.org/10.1016/j.semarthrit.2022.152110

Vancouver

Ghosh N, Couette N, van Binsbergen WH, Weinmann SC, Jivanelli B, Shea B et al. Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: A scoping review by the OMERACT irAE working group. Seminars in arthritis and rheumatism. 2023 Feb 1;58:152110. doi: 10.1016/j.semarthrit.2022.152110

Author

Ghosh, Nilasha ; Couette, Nina ; van Binsbergen, Wouter H. et al. / Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica : A scoping review by the OMERACT irAE working group. In: Seminars in arthritis and rheumatism. 2023 ; Vol. 58.

BibTeX

@article{018c4b5af8db47bca2e77558e4e2a8e1,
title = "Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: A scoping review by the OMERACT irAE working group",
abstract = "Introduction: Immune checkpoint inhibitors (ICI), increasingly used cancer therapeutics, can cause off-target inflammatory effects called immune-related adverse events (irAEs), including ICI-induced inflammatory arthritis (ICI-induced IA) and polymyalgia rheumatica (ICI-induced PMR). There are no validated classification criteria or outcome measures for these conditions, and adaptation of treatment recommendations from corresponding rheumatic diseases may not be appropriate. We summarized clinical descriptors of ICI-induced IA and ICI-induced PMR and aggregated domains used for these conditions in order to inform the development of a core set of outcome domains. Methods: As the initial step of the core domain set generation process, we systemically searched Medline (Pubmed), EMBASE, Cochrane, and CINHL through March 2021 to identify all studies that provide both clinical descriptions and domains relevant to ICI-induced IA and ICI-induced PMR. Domains were mapped to core areas, such as pathophysiological manifestations, life impact, resource use, and longevity/survival, as suggested by the OMERACT 2.1 Filter. Results: We identified 69 publications, over a third of which utilized non-specific diagnoses of “arthritis,” “arthralgia,” and/or “PMR”. Other publications provided the number, the distribution and/or names of specific joints affected, while others labeled the irAE as the corresponding rheumatic disease, such as rheumatoid arthritis or spondyloarthritis. Most distinct domains mapped to the pathophysiology/manifestations core area (24 domains), such as signs/symptoms (13 domains), labs (6 domains), and imaging (5 domains), with harm domains of adverse effects from irAE treatment and fear of irAE treatment decreasing ICI efficacy. Forty-three publications also referenced irAE treatment and 35 subsequent response, as well as 32 tumor response. Conclusion: There is considerable heterogeneity in the domains used to clinically characterize ICI-induced IA and ICI-induced PMR. There were several domains mapped to the pathophysiologic manifestations core area, although several publications highlighted domains evenly distributed among the other core areas of life impact, longevity/survival and resource use.",
keywords = "ICI-induced inflammatory arthritis, ICI-induced polymyalgia rheumatica, Immune checkpoint inhibitor, Outcome measures",
author = "Nilasha Ghosh and Nina Couette and {van Binsbergen}, {Wouter H.} and Weinmann, {Sophia C.} and Bridget Jivanelli and Beverley Shea and Bass, {Anne R.} and Karolina Benesova and Bingham, {Clifton O.} and Cassandra Calabrese and Cappelli, {Laura C.} and Chan, {Karmela Kim} and Ernest Choy and Dimitrios Daoussis and Susan Goodman and Marie Hudson and Shahin Jamal and Jan Leipe and Lopez-Olivo, {Maria A.} and Maria Suarez-Almazor and {van der Laken}, {Conny J.} and Meara, {Alexa Simon} and David Liew and Marie Kostine",
note = "Funding Information: We would like to submit this on behalf of the OMERACT irAE working group. We would also like to thank Marianne Visser, an OMERACT Patient Research Partner. In memoriam: Uwe Preckwinkel, an OMERACT Patient Research Partner. Uwe was a German scientist and a cancer patient who experienced a rheumatic immune-related adverse event. He was involved in the OMERACT working group on rheumatic immune-related adverse events since its inception. Publisher Copyright: {\textcopyright} 2022",
year = "2023",
month = feb,
day = "1",
doi = "10.1016/j.semarthrit.2022.152110",
language = "English",
volume = "58",
journal = "Seminars in arthritis and rheumatism",
issn = "0049-0172",
publisher = "W.B. Saunders Ltd",

}

RIS

TY - JOUR

T1 - Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica

T2 - A scoping review by the OMERACT irAE working group

AU - Ghosh, Nilasha

AU - Couette, Nina

AU - van Binsbergen, Wouter H.

AU - Weinmann, Sophia C.

AU - Jivanelli, Bridget

AU - Shea, Beverley

AU - Bass, Anne R.

AU - Benesova, Karolina

AU - Bingham, Clifton O.

AU - Calabrese, Cassandra

AU - Cappelli, Laura C.

AU - Chan, Karmela Kim

AU - Choy, Ernest

AU - Daoussis, Dimitrios

AU - Goodman, Susan

AU - Hudson, Marie

AU - Jamal, Shahin

AU - Leipe, Jan

AU - Lopez-Olivo, Maria A.

AU - Suarez-Almazor, Maria

AU - van der Laken, Conny J.

AU - Meara, Alexa Simon

AU - Liew, David

AU - Kostine, Marie

N1 - Funding Information: We would like to submit this on behalf of the OMERACT irAE working group. We would also like to thank Marianne Visser, an OMERACT Patient Research Partner. In memoriam: Uwe Preckwinkel, an OMERACT Patient Research Partner. Uwe was a German scientist and a cancer patient who experienced a rheumatic immune-related adverse event. He was involved in the OMERACT working group on rheumatic immune-related adverse events since its inception. Publisher Copyright: © 2022

PY - 2023/2/1

Y1 - 2023/2/1

N2 - Introduction: Immune checkpoint inhibitors (ICI), increasingly used cancer therapeutics, can cause off-target inflammatory effects called immune-related adverse events (irAEs), including ICI-induced inflammatory arthritis (ICI-induced IA) and polymyalgia rheumatica (ICI-induced PMR). There are no validated classification criteria or outcome measures for these conditions, and adaptation of treatment recommendations from corresponding rheumatic diseases may not be appropriate. We summarized clinical descriptors of ICI-induced IA and ICI-induced PMR and aggregated domains used for these conditions in order to inform the development of a core set of outcome domains. Methods: As the initial step of the core domain set generation process, we systemically searched Medline (Pubmed), EMBASE, Cochrane, and CINHL through March 2021 to identify all studies that provide both clinical descriptions and domains relevant to ICI-induced IA and ICI-induced PMR. Domains were mapped to core areas, such as pathophysiological manifestations, life impact, resource use, and longevity/survival, as suggested by the OMERACT 2.1 Filter. Results: We identified 69 publications, over a third of which utilized non-specific diagnoses of “arthritis,” “arthralgia,” and/or “PMR”. Other publications provided the number, the distribution and/or names of specific joints affected, while others labeled the irAE as the corresponding rheumatic disease, such as rheumatoid arthritis or spondyloarthritis. Most distinct domains mapped to the pathophysiology/manifestations core area (24 domains), such as signs/symptoms (13 domains), labs (6 domains), and imaging (5 domains), with harm domains of adverse effects from irAE treatment and fear of irAE treatment decreasing ICI efficacy. Forty-three publications also referenced irAE treatment and 35 subsequent response, as well as 32 tumor response. Conclusion: There is considerable heterogeneity in the domains used to clinically characterize ICI-induced IA and ICI-induced PMR. There were several domains mapped to the pathophysiologic manifestations core area, although several publications highlighted domains evenly distributed among the other core areas of life impact, longevity/survival and resource use.

AB - Introduction: Immune checkpoint inhibitors (ICI), increasingly used cancer therapeutics, can cause off-target inflammatory effects called immune-related adverse events (irAEs), including ICI-induced inflammatory arthritis (ICI-induced IA) and polymyalgia rheumatica (ICI-induced PMR). There are no validated classification criteria or outcome measures for these conditions, and adaptation of treatment recommendations from corresponding rheumatic diseases may not be appropriate. We summarized clinical descriptors of ICI-induced IA and ICI-induced PMR and aggregated domains used for these conditions in order to inform the development of a core set of outcome domains. Methods: As the initial step of the core domain set generation process, we systemically searched Medline (Pubmed), EMBASE, Cochrane, and CINHL through March 2021 to identify all studies that provide both clinical descriptions and domains relevant to ICI-induced IA and ICI-induced PMR. Domains were mapped to core areas, such as pathophysiological manifestations, life impact, resource use, and longevity/survival, as suggested by the OMERACT 2.1 Filter. Results: We identified 69 publications, over a third of which utilized non-specific diagnoses of “arthritis,” “arthralgia,” and/or “PMR”. Other publications provided the number, the distribution and/or names of specific joints affected, while others labeled the irAE as the corresponding rheumatic disease, such as rheumatoid arthritis or spondyloarthritis. Most distinct domains mapped to the pathophysiology/manifestations core area (24 domains), such as signs/symptoms (13 domains), labs (6 domains), and imaging (5 domains), with harm domains of adverse effects from irAE treatment and fear of irAE treatment decreasing ICI efficacy. Forty-three publications also referenced irAE treatment and 35 subsequent response, as well as 32 tumor response. Conclusion: There is considerable heterogeneity in the domains used to clinically characterize ICI-induced IA and ICI-induced PMR. There were several domains mapped to the pathophysiologic manifestations core area, although several publications highlighted domains evenly distributed among the other core areas of life impact, longevity/survival and resource use.

KW - ICI-induced inflammatory arthritis

KW - ICI-induced polymyalgia rheumatica

KW - Immune checkpoint inhibitor

KW - Outcome measures

UR - http://www.scopus.com/inward/record.url?scp=85141527194&partnerID=8YFLogxK

U2 - 10.1016/j.semarthrit.2022.152110

DO - 10.1016/j.semarthrit.2022.152110

M3 - Review article

C2 - 36372016

VL - 58

JO - Seminars in arthritis and rheumatism

JF - Seminars in arthritis and rheumatism

SN - 0049-0172

M1 - 152110

ER -

ID: 27114498